Introduction Empagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting urinary glucose excretion. It also provides cardiovascular and renal protective benefits, and is approved for type 2 diabetes mellitus, heart failure, and chronic kidney disease. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, taken once daily Bioavailability ~78% … Read more
Introduction Dapagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor, used to treat type 2 diabetes mellitus (T2DM). Additionally, it offers benefits in heart failure and chronic kidney disease, independent of its glucose-lowering effects. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, once daily Bioavailability ~78% Protein Binding ~91% Metabolism Glucuronidation (UGT1A9) Half-life … Read more
Introduction Jardiance (empagliflozin) is a sodium–glucose co-transporter 2 (SGLT2) inhibitor used for type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD). It lowers blood glucose by increasing renal glucose loss and offers cardiovascular and renal benefits. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral (tablet), once … Read more
Introduction Dapagliflozin (trade name Farxiga) is a sodium–glucose co‑transporter 2 (SGLT2) inhibitor used in type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF). It lowers blood glucose by promoting renal excretion of glucose and also provides cardiovascular and renal benefits beyond glycemic control. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral … Read more
